The endocannabinoid/endovanilloid N-Arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells

Journal of Biological Chemistry

Volumn 289, Issue 19, 2014, Pages 13079-13100

  Wilhelmsen, Kevin ^a   Khakpour, Samira ^b   Tran, Alphonso ^a   Sheehan, Kayla ^a   Schumacher, Mark ^a   Xu, Fengyun ^a   Hellman, Judith ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINES; ENDOTHELIAL CELLS; POSITIVE IONS;

ANTI-INFLAMMATORIES; HUMAN ENDOTHELIAL CELLS; IMMUNOMODULATORY ACTIVITIES; INFLAMMATORY DISORDERS; INFLAMMATORY RESPONSE; METABOLIC ENZYMES; SYNTHETIC CANNABINOID; TRANSIENT RECEPTOR POTENTIALS;

NEUROPHYSIOLOGY;

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CYTOKINE; ENDOCANNABINOID; ENDOVANILLOID N ARACHIDONOYL DOPAMINE; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 18; G PROTEIN COUPLED RECEPTOR 55; LIPOPEPTIDE; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1; WIN 55 212 2;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CELL ADHESION; CELL POPULATION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG POTENCY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; INFLAMMATION; LEUKOCYTE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CANNABINOID RECEPTORS; CANNABINOIDS; ENDOCANNABINOIDS; ENDOTHELIAL CELL; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; SEPSIS; TOLL-LIKE RECEPTORS (TLR); TRP CHANNELS;

ANALGESICS; ARACHIDONIC ACIDS; BACTERIAL PROTEINS; BENZOXAZINES; CANNABINOIDS; DOPAMINE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; LIPOPEPTIDES; MORPHOLINES; NAPHTHALENES; RECEPTORS, CANNABINOID; TRPV CATION CHANNELS;

EID: 84900425931     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.536953     Document Type: Article

References (157)

1. Pertwee, R. G., Howlett, A. C., Abood, M. E., Alexander, S. P., Di Marzo, V., Elphick, M. R., Greasley, P. J., Hansen, H. S., Kunos, G., Mackie, K., Mechoulam, R., and Ross, R. A. (2010) International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB (1) and CB (2). Pharmacol. Rev. 62, 588-631
2. Pertwee, R. G. (2006) Cannabinoid pharmacology: the first 66 years. Br. J. Pharmacol. 147, S163-S171
3. De Petrocellis, L., and Di Marzo, V. (2009) An introduction to the endocannabinoid system: from the early to the latest concepts. Best Pract. Res. Clin. Endocrinol. Metab. 23, 1-15
4. Ueda, N., Tsuboi, K., and Uyama, T. (2013) Metabolism of endocannabinoids and related N-Acylethanolamines: canonical and alternative pathways. FEBS J. 280, 1874-1894
5. Castillo, P. E., Younts, T. J., Chávez, A. E., and Hashimotodani, Y. (2012) Endocannabinoid signaling and synaptic function. Neuron 76, 70-81
6. Elphick, M. R. (2012) The evolution and comparative neurobiology of endocannabinoid signalling. Philos. Trans. R. Soc. Lond. B Biol. Sci. 367, 3201-3215
7. Luchicchi, A., and Pistis, M. (2012) Anandamide and 2- Arachidonoylglycerol: pharmacological properties, functional features, and emerging specificities of the two major endocannabinoids. Mol. Neurobiol. 46, 374-392
8. Piomelli, D. (2014) More surprises lying ahead. The endocannabinoids keep us guessing. Neuropharmacology 76, 228-234
9. Galiègue, S., Mary, S., Marchand, J., Dussossoy, D., Carrière, D., Carayon, P., Bouaboula, M., Shire, D., Le Fur, G., and Casellas, P. (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 232, 54-61
10. Graham, E. S., Angel, C. E., Schwarcz, L. E., Dunbar, P. R., and Glass, M. (2010) Detailed characterisation of CB2 receptor protein expression in peripheral blood immune cells from healthy human volunteers using flow cytometry. Int. J. Immunopathol. Pharmacol. 23, 25-34
11. Lee, S. F., Newton, C., Widen, R., Friedman, H., and Klein, T. W. (2001) Differential expression of cannabinoid CB (2) receptor mRNA in mouse immune cell subpopulations and following B cell stimulation. Eur. J. Pharmacol. 423, 235-241
12. Rom, S., and Persidsky, Y. (2013) Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation. J. Neuroimmune Pharmacol. 8, 608-620
13. Tschöp, J., Kasten, K. R., Nogueiras, R., Goetzman, H. S., Cave, C. M., England, L. G., Dattilo, J., Lentsch, A. B., Tschöp, M. H., and Caldwell, C. C. (2009) The cannabinoid receptor 2 is critical for the host response to sepsis. J. Immunol. 183, 499-505
14. Kasten, K. R., Tschöp, J., Tschöp, M. H., and Caldwell, C. C. (2010) The cannabinoid 2 receptor as a potential therapeutic target for sepsis. Endocr. Metab. Immune Disord. Drug Targets 10, 224-234
15. Gui, H., Sun, Y., Luo, Z. M., Su, D. F., Dai, S. M., and Liu, X. (2013) Cannabinoid receptor 2 protects against acute experimental sepsis in mice. Mediators Inflamm. 2013, 741303
16. Nagarkatti, P., Pandey, R., Rieder, S. A., Hegde, V. L., and Nagarkatti, M. (2009) Cannabinoids as novel anti-inflammatory drugs. Future Med. Chem. 1, 1333-1349
17. Klein, T. W., Newton, C., Larsen, K., Lu, L., Perkins, I., Nong, L., and Friedman, H. (2003) The cannabinoid system and immune modulation. J. Leukocyte Biol. 74, 486-496
18. Kozela, E., Pietr, M., Juknat, A., Rimmerman, N., Levy, R., and Vogel, Z. (2010) Cannabinoids Δ (9) -tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-Activated NF-κB and interferon-α/STAT proinflammatory pathways in BV-2 microglial cells. J. Biol. Chem. 285, 1616-1626
19. Lee, W. L., and Liles, W. C. (2011) Endothelial activation, dysfunction and permeability during severe infections. Curr. Opin. Hematol. 18, 191-196
20. Shin, H. S., Xu, F., Bagchi, A., Herrup, E., Prakash, A., Valentine, C., Kulkarni, H., Wilhelmsen, K., Warren, S., and Hellman, J. (2011) Bacterial lipoprotein TLR2 agonists broadly modulate endothelial function and coagulation pathways in vitro and in vivo. J. Immunol. 186, 1119-1130
21. Wilhelmsen, K., Mesa, K. R., Lucero, J., Xu, F., and Hellman, J. (2012) ERK5 protein promotes, whereas MEK1 protein differentially regulates, the Toll-like receptor 2 protein-dependent activation of human endothelial cells and monocytes. J. Biol. Chem. 287, 26478-26494
22. Wilhelmsen, K., Mesa, K. R., Prakash, A., Xu, F., and Hellman, J. (2012) Activation of endothelial TLR2 by bacterial lipoprotein upregulates proteins specific for the neutrophil response. Innate Immun. 18, 602-616
23. Aird, W. C. (2003) The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 101, 3765-3777
24. Makó, V., Czúcz, J., Weiszhár, Z., Herczenik, E., Matkó, J., Prohászka, Z., and Cervenak, L. (2010) Proinflammatory activation pattern of human umbilical vein endothelial cells induced by IL-1β, TNF-α, and LPS. Cytometry 77, 962-970
25. Croxford, J. L., and Yamamura, T. (2005) Cannabinoids and the immune system: potential for the treatment of inflammatory diseases? J. Neuroimmunol. 166, 3-18
26. Facchinetti, F., Del Giudice, E., Furegato, S., Passarotto, M., and Leon, A. (2003) Cannabinoids ablate release of TNFα in rat microglial cells stimulated with lipopolysaccharide. Glia 41, 161-168
27. Hao, M. X., Jiang, L. S., Fang, N. Y., Pu, J., Hu, L. H., Shen, L. H., Song, W., and He, B. (2010) The cannabinoid WIN55, 212-2 protects against oxidized LDL-induced inflammatory response in murine macrophages. J. Lipid Res. 51, 2181-2190
28. Li, Y. Y., Yuece, B., Cao, H. M., Lin, H. X., Lv, S., Chen, J. C., Ochs, S., Sibaev, A., Deindl, E., Schaefer, C., and Storr, M. (2013) Inhibition of p38/Mk2 signaling pathway improves the anti-inflammatory effect of WIN55 on mouse experimental colitis. Lab. Investig. 93, 322-333
29. Mestre, L., Docagne, F., Correa, F., Loría, F., Hernangómez, M., Borrell, J., and Guaza, C. (2009) A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules. Mol. Cell. Neurosci. 40, 258-266
30. Sheng, W. S., Hu, S., Min, X., Cabral, G. A., Lokensgard, J. R., and Peterson, P. K. (2005) Synthetic cannabinoid WIN55, 212-2 inhibits generation of inflammatory mediators by IL-1β-stimulated human astrocytes. Glia 49, 211-219
31. Mormina, M. E., Thakur, S., Molleman, A., Whelan, C. J., and Baydoun, A. R. (2006) Cannabinoid signalling in TNF-α induced IL-8 release. Eur. J. Pharmacol. 540, 183-190
32. Croxford, J. L., Wang, K., Miller, S. D., Engman, D. M., and Tyler, K. M. (2005) Effects of cannabinoid treatment on Chagas disease pathogenesis: balancing inhibition of parasite invasion and immunosuppression. Cell. Microbiol. 7, 1592-1602
33. Bisogno, T., Melck, D., Bobrov M Yu, Gretskaya, N. M., Bezuglov, V. V., De Petrocellis, L., and Di Marzo, V. (2000) N-Acyl-dopamines: novel synthetic CB (1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem. J. 351, 817-824
34. Huang, S. M., Bisogno, T., Trevisani, M., Al-Hayani, A., De Petrocellis, L., Fezza, F., Tognetto, M., Petros, T. J., Krey, J. F., Chu, C. J., Miller, J. D., Davies, S. N., Geppetti, P., Walker, J. M., and Di Marzo, V. (2002) An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc. Natl. Acad. Sci. U. S. A. 99, 8400-8405
35. Bezuglov, V., Bobrov, M., Gretskaya, N., Gonchar, A., Zinchenko, G., Melck, D., Bisogno, T., Di Marzo, V., Kuklev, D., Rossi, J. C., Vidal, J. P., and Durand, T. (2001) Synthesis and biological evaluation of novel amides of polyunsaturated fatty acids with dopamine. Bioorg. Med. Chem. Lett. 11, 447-449
36. Little, P. J., Compton, D. R., Johnson, M. R., Melvin, L. S., and Martin, B. R. (1988) Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J. Pharmacol. Exp. Ther. 247, 1046-1051
37. Martin, B. R., Compton, D. R., Thomas, B. F., Prescott, W. R., Little, P. J., Razdan, R. K., Johnson, M. R., Melvin, L. S., Mechoulam, R., and Ward, S. J. (1991) Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol. Biochem. Behav. 40, 471-478
38. Huang, S. M., and Walker, J. M. (2006) Enhancement of spontaneous and heat-evoked activity in spinal nociceptive neurons by the endovanilloid/ endocannabinoid N-Arachidonoyldopamine (NADA). J. Neurophysiol. 95, 1207-1212
39. Marinelli, S., Di Marzo, V., Florenzano, F., Fezza, F., Viscomi, M. T., Van Der Stelt, M., Bernardi, G., Molinari, M., Maccarrone, M., and Mercuri, N. B. (2007) N-Arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors. Neuropsychopharmacology 32, 298-308
40. Price, T. J., Patwardhan, A., Akopian, A. N., Hargreaves, K. M., and Flores, C. M. (2004) Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-Arachidonoyldopamine and arachidonyl-2-chloroethylamide. Br. J. Pharmacol. 141, 1118-1130
41. Sagar, D. R., Smith, P. A., Millns, P. J., Smart, D., Kendall, D. A., and Chapman, V. (2004) TRPV1 and CB (1) receptor-mediated effects of the endovanilloid/endocannabinoid N-Arachidonoyl-dopamine on primary afferent fibre and spinal cord neuronal responses in the rat. Eur. J. Neurosci. 20, 175-184
42. Bobrov, M. Y., Lizhin, A. A., Andrianova, E. L., Gretskaya, N. M., Frumkina, L. E., Khaspekov, L. G., and Bezuglov, V. V. (2008) Antioxidant and neuroprotective properties of N-Arachidonoyldopamine. Neurosci. Lett. 431, 6-11
43. Harrison, S., De Petrocellis, L., Trevisani, M., Benvenuti, F., Bifulco, M., Geppetti, P., and Di Marzo, V. (2003) Capsaicin-like effects of N-Arachidonoyldopamine in the isolated guinea pig bronchi and urinary bladder. Eur. J. Pharmacol. 475, 107-114
44. O'Sullivan, S. E., Kendall, D. A., and Randall, M. D. (2004) Characterisation of the vasorelaxant properties of the novel endocannabinoid Narachidonoyldopamine (NADA). Br. J. Pharmacol. 141, 803-812
45. O'Sullivan, S. E., Kendall, D. A., and Randall, M. D. (2009) Time-dependent vascular effects of endocannabinoids mediated by peroxisome proliferatoractivated receptor γ (PPARγ). PPAR Res. 2009, 425289
46. Navarrete, C. M., Fiebich, B. L., De Vinuesa, A. G., Hess, S., De Oliveira, A. C., Candelario-Jalil, E., Caballero, F. J., Calzado, M. A., and Muñoz, E. (2009) Opposite effects of anandamide and N-Arachidonoyl dopamine in the regulation of prostaglandin E and 8-iso-PGF formation in primary glial cells. J. Neurochem. 109, 452-464
47. Navarrete, C. M., Pérez, M., De Vinuesa, A. G., Collado, J. A., Fiebich, B. L., Calzado, M. A., and Muñoz, E. (2010) Endogenous N-Acyl-dopamines induce COX-2 expression in brain endothelial cells by stabilizing mRNA through a p38-dependent pathway. Biochem. Pharmacol. 79, 1805-1814
48. Sancho, R., Macho, A., De La Vega, L., Calzado, M. A., Fiebich, B. L., Appendino, G., and Muñoz, E. (2004) Immunosuppressive activity of endovanilloids: N-Arachidonoyl-dopamine inhibits activation of the NF-κB, NFAT, and activator protein 1 signaling pathways. J. Immunol. 172, 2341-2351
49. Sancho, R., De La Vega, L., Macho, A., Appendino, G., Di Marzo, V., and Muñoz, E. (2005) Mechanisms of HIV-1 inhibition by the lipid mediator N-Arachidonoyldopamine. J. Immunol. 175, 3990-3999
50. Yoo, J. M., Park, E. S., Kim, M. R., and Sok, D. E. (2013) Inhibitory effect of N-Acyl dopamines on IgE-mediated allergic response in RBL-2H3 cells. Lipids 48, 383-393
51. Felder, C. C., Joyce, K. E., Briley, E. M., Mansouri, J., Mackie, K., Blond, O., Lai, Y., Ma, A. L., and Mitchell, R. L. (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol. 48, 443-450
52. De Petrocellis, L., Bisogno, T., Davis, J. B., Pertwee, R. G., and Di Marzo, V. (2000) Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett. 483, 52-56
53. Patwardhan, A. M., Jeske, N. A., Price, T. J., Gamper, N., Akopian, A. N., and Hargreaves, K. M. (2006) The cannabinoid WIN 55, 212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin. Proc. Natl. Acad. Sci. U. S. A. 103, 11393-11398
54. Jeske, N. A., Patwardhan, A. M., Gamper, N., Price, T. J., Akopian, A. N., and Hargreaves, K. M. (2006) Cannabinoid WIN 55, 212-2 regulates TRPV1 phosphorylation in sensory neurons. J. Biol. Chem. 281, 32879-32890
55. Wilhelmsen, K., Farrar, K., and Hellman, J. (2013) Quantitative in vitro assay to measure neutrophil adhesion to activated primary human microvascular endothelial cells under static conditions. J. Vis. Exp. 78, e50677
56. Livak, K. J., and Schmittgen, T. D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2 (ΔΔC (T)) Method. Methods 25, 402-408
57. Willems, E., Leyns, L., and Vandesompele, J. (2008) Standardization of real-time PCR gene expression data from independent biological replicates. Anal. Biochem. 379, 127-129
58. Giaever, I., and Keese, C. R. (1991) Micromotion of mammalian cells measured electrically. Proc. Natl. Acad. Sci. U. S. A. 88, 7896-7900
59. Zavala, K., Lee, J., Chong, J., Sharma, M., Eilers, H., and Schumacher, M. A. (2014) The anticancer antibiotic mithramycin-A inhibits TRPV1 expression in dorsal root ganglion neurons. Neurosci. Lett. 10.1016/j.neulet.2014.01.021
60. Eilers, H., Lee, S. Y., Hau, C. W., Logvinova, A., and Schumacher, M. A. (2007) The rat vanilloid receptor splice variant VR. 5βsv blocks TRPV1 activation. Neuroreport 18, 969-973
61. Szallasi, A., Cortright, D. N., Blum, C. A., and Eid, S. R. (2007) The vanilloid receptor TRPV1:10 years from channel cloning to antagonist proof of concept. Nat. Rev. Drug Discov. 6, 357-372
62. Gavva, N. R., Tamir, R., Qu, Y., Klionsky, L., Zhang, T. J., Immke, D., Wang, J., Zhu, D., Vanderah, T. W., Porreca, F., Doherty, E. M., Norman, M. H., Wild, K. D., Bannon, A. W., Louis, J. C., and Treanor, J. J. (2005) MG9810 [(E) -3-(4-t-Butylphenyl) -N-(2, 3-dihydrobenzo[b][1, 4]dioxin-6-yl) acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties. J. Pharmacol. Exp. Ther. 313, 474-484
63. Holladay, C. S., Wright, R. M., and Spangelo, B. L. (1993) Arachidonic acid stimulates interleukin-6 release from rat peritoneal macrophages in vitro: evidence for a prostacyclin-dependent mechanism. Prostaglandins Leukot. Essent. Fatty Acids 49, 915-922
64. Wojtalla, A., Herweck, F., Granzow, M., Klein, S., Trebicka, J., Huss, S., Lerner, R., Lutz, B., Schildberg, F. A., Knolle, P. A., Sauerbruch, T., Singer, M. V., Zimmer, A., and Siegmund, S. V. (2012) The endocannabinoid N-Arachidonoyl dopamine (NADA) selectively induces oxidative stressmediated cell death in hepatic stellate cells but not in hepatocytes. Am. J. Physiol. Gastrointest. Liver Physiol. 302, G873-G887
65. Griffith, D. A., Hadcock, J. R., Black, S. C., Iredale, P. A., Carpino, P. A., Da Silva-Jardine, P., Day, R., Di Brino, J., Dow, R. L., Landis, M. S., O'Connor, R. E., and Scott, D. O. (2009) Discovery of 1-[9-(4-chlorophenyl) -8-(2-chlorophenyl) -9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic acid amide hydrochloride (CP-945, 598), a novel, potent, and selective cannabinoid type 1 receptor antagonist. J. Med. Chem. 52, 234-237
66. Portier, M., Rinaldi-Carmona, M., Pecceu, F., Combes, T., Poinot-Chazel, C., Calandra, B., Barth, F., Le Fur, G., and Casellas, P. (1999) SR 144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist. J. Pharmacol. Exp. Ther. 288, 582-589
67. Rinaldi-Carmona, M., Barth, F., Millan, J., Derocq, J. M., Casellas, P., Congy, C., Oustric, D., Sarran, M., Bouaboula, M., Calandra, B., Portier, M., Shire, D., Brelière, J. C., and Le Fur, G. L. (1998) SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 284, 644-650
68. Billstrom, M. A., Johnson, G. L., Avdi, N. J., and Worthen, G. S. (1998) Intracellular signaling by the chemokine receptor US28 during human cytomegalovirus infection. J. Virol. 72, 5535-5544
69. Akimov, M. G., Gretskaia, N. M., Shevchenko, K. V., Shevchenko, V. P., Miasoedov, N. F., Bobrov MIu, and Bezuglov, V. V. (2007) New aspects of biosynthesis and metabolism of N-Acyldopamines in rat tissues. Bioorganicheskaia khimiia 33, 648-652
70. Hu, S. S., Bradshaw, H. B., Benton, V. M., Chen, J. S., Huang, S. M., Minassi, A., Bisogno, T., Masuda, K., Tan, B., Roskoski, R., Jr., Cravatt, B. F., Di Marzo, V., and Walker, J. M. (2009) The biosynthesis of Narachidonoyl dopamine (NADA), a putative endocannabinoid and endovanilloid, via conjugation of arachidonic acid with dopamine. Prostaglandins Leukot. Essent. Fatty Acids 81, 291-301
71. Huang, N. L., Juang, J. M., Wang, Y. H., Hsueh, C. H., Liang, Y. J., Lin, J. L., Tsai, C. T., and Lai, L. P. (2010) Rimonabant inhibits TNF-α-induced endothelial IL-6 secretion via CB1 receptor and cAMP-dependent protein kinase pathway. Acta Pharmacol. Sin. 31, 1447-1453
72. Liu, J., Gao, B., Mirshahi, F., Sanyal, A. J., Khanolkar, A. D., Makriyannis, A., and Kunos, G. (2000) Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem. J. 346, 835-840
73. Rajesh, M., Mukhopadhyay, P., Bátkai, S., Haskó, G., Liaudet, L., Huffman, J. W., Csiszar, A., Ungvari, Z., Mackie, K., Chatterjee, S., and Pacher, P. (2007) CB2-receptor stimulation attenuates TNF-α-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am. J. Physiol. Heart Circ. Physiol. 293, H2210-H2218
74. Rajesh, M., Mukhopadhyay, P., Haskó, G., Liaudet, L., Mackie, K., and Pacher, P. (2010) Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and -independent mitogen-Activated protein kinase activation and cell death in human coronary artery endothelial cells. Br. J. Pharmacol. 160, 688-700
75. Sugiura, T., Kodaka, T., Nakane, S., Kishimoto, S., Kondo, S., and Waku, K. (1998) Detection of an endogenous cannabimimetic molecule, 2-Arachidonoylglycerol, and cannabinoid CB1 receptormRNAin human vascular cells: is 2-Arachidonoylglycerol a possible vasomodulator? Biochem. Biophys. Res. Commun. 243, 838-843
76. 2+ signaling in endothelial cells via GPR55 by protection against CB1-receptor-triggered repression. J. Cell Sci. 121, 1704-1717
77. Ramirez, S. H., Haskó, J., Skuba, A., Fan, S., Dykstra, H., McCormick, R., Reichenbach, N., Krizbai, I., Mahadevan, A., Zhang, M., Tuma, R., Son, Y. J., and Persidsky, Y. (2012) Activation of cannabinoid receptor 2 attenuates leukocyte-endothelial cell interactions and blood-brain barrier dysfunction under inflammatory conditions. J. Neurosci. 32, 4004-4016
78. Golech, S. A., McCarron, R. M., Chen, Y., Bembry, J., Lenz, F., Mechoulam, R., Shohami, E., and Spatz, M. (2004) Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. Brain Res. Mol. Brain Res. 132, 87-92
79. Lu, T. S., Avraham, H. K., Seng, S., Tachado, S. D., Koziel, H., Makriyannis, A., and Avraham, S. (2008) Cannabinoids inhibit HIV-1 Gp120-mediated insults in brain microvascular endothelial cells. J. Immunol. 181, 6406-6416
80. Alhouayek, M., Masquelier, J., and Muccioli, G. G. (2014) Controlling 2-Arachidonoylglycerol metabolism as an anti-inflammatory strategy. Drug Discov. Today 19, 295-304
81. Bátkai, S., Rajesh, M., Mukhopadhyay, P., Haskó, G., Liaudet, L., Cravatt, B. F., Csiszár, A., Ungvári, Z., and Pacher, P. (2007) Decreased age-related cardiac dysfunction, myocardial nitrative stress, inflammatory gene expression, and apoptosis in mice lacking fatty acid amide hydrolase. Am. J. Physiol. Heart Circ. Physiol. 293, H909-H918
82. Chang, Y. H., Lee, S. T., and Lin, W. W. (2001) Effects of cannabinoids on LPS-stimulated inflammatory mediator release from macrophages: involvement of eicosanoids. J. Cell. Biochem. 81, 715-723
83. Gallily, R., Breuer, A., and Mechoulam, R. (2000) 2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-α production in murine macrophages, and in mice. Eur. J. Pharmacol. 406, R5-R7
84. Opitz, C. A., Rimmerman, N., Zhang, Y., Mead, L. E., Yoder, M. C., Ingram, D. A., Walker, J. M., and Rehman, J. (2007) Production of the endocannabinoids anandamide and 2-Arachidonoylglycerol by endothelial progenitor cells. FEBS Lett. 581, 4927-4931
85. Ouyang, Y., Hwang, S. G., Han, S. H., and Kaminski, N. E. (1998) Suppression of interleukin-2 by the putative endogenous cannabinoid 2-Arachidonyl-glycerol is mediated through down-regulation of the nuclear factor of activated T cells. Mol. Pharmacol. 53, 676-683
86. Björklund, E., Norén, E., Nilsson, J., and Fowler, C. J. (2010) Inhibition of monoacylglycerol lipase by troglitazone, N-Arachidonoyl dopamine and the irreversible inhibitor JZL184: comparison of two different assays. Br. J. Pharmacol. 161, 1512-1526
87. Gokoh, M., Kishimoto, S., Oka, S., Metani, Y., and Sugiura, T. (2005) 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, enhances the adhesion of HL-60 cells differentiated into macrophagelike cells and human peripheral blood monocytes. FEBS Lett. 579, 6473-6478
88. Sugiura, T. (2009) Physiological roles of 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Biofactors 35, 88-97
89. Sugiura, T., Oka, S., Gokoh, M., Kishimoto, S., and Waku, K. (2004) New perspectives in the studies on endocannabinoid and cannabis: 2-Arachidonoylglycerol as a possible novel mediator of inflammation. J. Pharmacol. Sci. 96, 367-375
90. De Petrocellis, L., Bisogno, T., Maccarrone, M., Davis, J. B., Finazzi-Agro, A., and Di Marzo, V. (2001) The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J. Biol. Chem. 276, 12856-12863
91. 2+ signalling. Cell Calcium 45, 611-624
92. Jordt, S. E., and Julius, D. (2002) Molecular basis for species-specific sensitivity to "hot" chili peppers. Cell 108, 421-430
93. Chu, C. J., Huang, S. M., De Petrocellis, L., Bisogno, T., Ewing, S. A., Miller, J. D., Zipkin, R. E., Daddario, N., Appendino, G., Di Marzo, V., and Walker, J. M. (2003) N-Oleoyldopamine, a novel endogenous capsaicinlike lipid that produces hyperalgesia. J. Biol. Chem. 278, 13633-13639
94. Millns, P. J., Chimenti, M., Ali, N., Ryland, E., De Lago, E., Fernandez-Ruiz, J., Chapman, V., and Kendall, D. A. (2006) Effects of inhibition of fatty acid amide hydrolase vs. The anandamide membrane transporter on TRPV1-mediated calcium responses in adult DRG neurons; the role of CB receptors. Eur. J. Neurosci. 24, 3489-3495
95. Price, T. J., Patwardhan, A. M., Flores, C. M., and Hargreaves, K. M. (2005) A role for the anandamide membrane transporter in TRPV1-mediated neurosecretion from trigeminal sensory neurons. Neuropharmacology 49, 25-39
96. Premkumar, L. S., Qi, Z. H., Van Buren, J., and Raisinghani, M. (2004) Enhancement of potency and efficacy of NADA by PKC-mediated phosphorylation of vanilloid receptor. J. Neurophysiol. 91, 1442-1449
97. Vellani, V., Mapplebeck, S., Moriondo, A., Davis, J. B., and McNaughton, P. A. (2001) Protein kinaseCactivation potentiates gating of the vanilloid receptor VR1 by capsaicin, protons, heat and anandamide. J. Physiol. 534, 813-825
98. Olah, Z., Karai, L., and Iadarola, M. J. (2001) Anandamide activates vanilloid receptor 1 (VR1) at acidic pH in dorsal root ganglia neurons and cells ectopically expressing VR1. J. Biol. Chem. 276, 31163-31170
99. Kwak, J., Wang, M. H., Hwang, S. W., Kim, T. Y., Lee, S. Y., and Oh, U. (2000) Intracellular ATP increases capsaicin-Activated channel activity by interacting with nucleotide-binding domains. J. Neurosci. 20, 8298-8304
100. Kumar, P., Shen, Q., Pivetti, C. D., Lee, E. S., Wu, M. H., and Yuan, S. Y. (2009) Molecular mechanisms of endothelial hyperpermeability: implications in inflammation. Expert Rev. Mol. Med. 11, e19
101. 2+ signaling, TRP channels, and endothelial permeability. Microcirculation 13, 693-708
102. Talreja, J., Kabir, M. H., Filla, M., Stechschulte, D. J., and Dileepan, K. N. (2004) Histamine induces Toll-like receptor 2 and 4 expression in endothelial cells and enhances sensitivity to Gram-positive and Gram-negative bacterial cell wall components. Immunology 113, 224-233
103. Andriopoulou, P., Navarro, P., Zanetti, A., Lampugnani, M. G., and Dejana, E. (1999) Histamine induces tyrosine phosphorylation of endothelial cell-to-cell adherens junctions. Arterioscler. Thromb. Vasc. Biol. 19, 2286-2297
104. Schaefer, U., Schneider, A., Rixen, D., and Neugebauer, E. (1998) Neutrophil adhesion to histamine stimulated cultured endothelial cells is primarily mediated via activation of phospholipase C and nitric oxide synthase isozymes. Inflamm. Res. 47, 256-264
105. Jeannin, P., Delneste, Y., Gosset, P., Molet, S., Lassalle, P., Hamid, Q., Tsicopoulos, A., and Tonnel, A. B. (1994) Histamine induces interleukin-8 secretion by endothelial cells. Blood 84, 2229-2233
106. Pertwee, R. G. (2010) Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr. Med. Chem. 17, 1360-1381
107. Chang, W. C. (2006) Store-operated calcium channels and pro-inflammatory signals. Acta Pharmacol. Sin. 27, 813-820
108. 2+ influx channels in leukocytes: a therapeutic target? Trends Pharmacol. Sci. 23, 63-70
109. Liu, W., and Matsumori, A. (2011) Calcium channel blockers and modulation of innate immunity. Curr. Opin. Infect. Dis. 24, 254-258
110. Southall, M. D., Li, T., Gharibova, L. S., Pei, Y., Nicol, G. D., and Travers, J. B. (2003) Activation of epidermal vanilloid receptor-1 induces release of proinflammatory mediators in human keratinocytes. J. Pharmacol. Exp. Ther. 304, 217-222
111. Prusakiewicz, J. J., Turman, M. V., Vila, A., Ball, H. L., Al-Mestarihi, A. H., Di Marzo, V., and Marnett, L. J. (2007) Oxidative metabolism of lipoamino acids and vanilloids by lipoxygenases and cyclooxygenases. Arch. Biochem. Biophys. 464, 260-268
112. Ross, H. R., Gilmore, A. J., and Connor, M. (2009) Inhibition of human recombinant T-type calcium channels by the endocannabinoid N-Arachidonoyl dopamine. Br. J. Pharmacol. 156, 740-750
113. Tseng, C. F., Iwakami, S., Mikajiri, A., Shibuya, M., Hanaoka, F., Ebizuka, Y., Padmawinata, K., and Sankawa, U. (1992) Inhibition of in vitro prostaglandin and leukotriene biosyntheses by cinnamoyl-β-phenethylamine and N-Acyldopamine derivatives. Chem. Pharm. Bull. 40, 396-400
114. Sun, Y., Alexander, S. P., Kendall, D. A., and Bennett, A. J. (2006) Cannabinoids and PPARα signalling. Biochem. Soc. Trans. 34, 1095-1097
115. De Petrocellis, L., Starowicz, K., Moriello, A. S., Vivese, M., Orlando, P., and Di Marzo, V. (2007) Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB (1) receptors and endovanilloids. Exp. Cell Res. 313, 1911-1920
116. Salas, M. M., Hargreaves, K. M., and Akopian, A. N. (2009) TRPA1-mediated responses in trigeminal sensory neurons: interaction between TRPA1 and TRPV1. Eur. J. Neurosci. 29, 1568-1578
117. Reddy, A. T., Lakshmi, S. P., Kleinhenz, J. M., Sutliff, R. L., Hart, C. M., and Reddy, R. C. (2012) Endothelial cell peroxisome proliferator-Activated receptor γ reduces endotoxemic pulmonary inflammation and injury. J. Immunol. 189, 5411-5420
118. Sasaki, M., Jordan, P., Welbourne, T., Minagar, A., Joh, T., Itoh, M., Elrod, J. W., and Alexander, J. S. (2005) Troglitazone, a PPAR-γ activator prevents endothelial cell adhesion molecule expression and lymphocyte adhesion mediated by TNF-α. BMC Physiol. 5, 3
119. Zandbergen, F., and Plutzky, J. (2007) PPARα in atherosclerosis and inflammation. Biochim. Biophys. Acta 1771, 972-982
120. Agro, A., Langdon, C., Smith, F., and Richards, C. D. (1996) Prostaglandin E2 enhances interleukin 8 (IL-8) and IL-6 but inhibits GMCSF production by IL-1 stimulated human synovial fibroblasts in vitro. J. Rheumatol. 23, 862-868
121. Ricciotti, E., and Fitz Gerald, G. A. (2011) Prostaglandins and inflammation. Arterioscler. Thromb. Vasc. Biol. 31, 986-1000
122. Turu, G., and Hunyady, L. (2010) Signal transduction of the CB1 cannabinoid receptor. J. Mol. Endocrinol. 44, 75-85
123. Bhave, G., Zhu, W., Wang, H., Brasier, D. J., Oxford, G. S., and Gereau, R. W., 4th (2002) cAMP-dependent protein kinase regulates desensitization of the capsaicin receptor (VR1) by direct phosphorylation. Neuron 35, 721-731
124. Alawi, K., and Keeble, J. (2010) The paradoxical role of the transient receptor potential vanilloid 1 receptor in inflammation. Pharmacol. Ther. 125, 181-195
125. Clark, N., Keeble, J., Fernandes, E. S., Starr, A., Liang, L., Sugden, D., De Winter, P., and Brain, S. D. (2007) The transient receptor potential vanilloid 1 (TRPV1) receptor protects against the onset of sepsis after endotoxin. FASEB J. 21, 3747-3755
126. Fernandes, E. S., Liang, L., Smillie, S. J., Kaiser, F., Purcell, R., Rivett, D. W., Alam, S., Howat, S., Collins, H., Thompson, S. J., Keeble, J. E., Riffo-Vasquez, Y., Bruce, K. D., and Brain, S. D. (2012) TRPV1 deletion enhances local inflammation and accelerates the onset of systemic inflammatory response syndrome. J. Immunol. 188, 5741-5751
127. Wang, H., Yu, M., Ochani, M., Amella, C. A., Tanovic, M., Susarla, S., Li, J. H., Wang, H., Yang, H., Ulloa, L., Al-Abed, Y., Czura, C. J., and Tracey, K. J. (2003) Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation. Nature 421, 384-388
128. Rosas-Ballina, M., Olofsson, P. S., Ochani, M., Valdés-Ferrer, S. I., Levine, Y. A., Reardon, C., Tusche, M. W., Pavlov, V. A., Andersson, U., Chavan, S., Mak, T. W., and Tracey, K. J. (2011) Acetylcholine- synthesizingTcells relay neural signals in a vagus nerve circuit. Science 334, 98-101
129. Tracey, K. J. (2009) Reflex control of immunity. Nat. Rev. Immunol. 9, 418-428
130. Bradshaw, H. B., Rimmerman, N., Krey, J. F., and Walker, J. M. (2006) Sex and hormonal cycle differences in rat brain levels of pain-related cannabimimetic lipid mediators. Am. J. Physiol. Regul. Integr. Comp. Physiol. 291, R349-R358
131. Hamel, E. (2006) Perivascular nerves and the regulation of cerebrovascular tone. J. Appl. Physiol. 100, 1059-1064
132. Girouard, H., and Iadecola, C. (2006) Neurovascular coupling in the normal brain and in hypertension, stroke, and Alzheimer disease. J. Appl. Physiol. 100, 328-335
133. Goyal, R. K., and Chaudhury, A. (2013) Structure activity relationship of synaptic and junctional neurotransmission. Auton. Neurosci. 176, 11-31
134. De Petrocellis, L., and Di Marzo, V. (2010) Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels. J. Neuroimmune Pharmacol. 5, 103-121
135. McHugh, D., Hu, S. S., Rimmerman, N., Juknat, A., Vogel, Z., Walker, J. M., and Bradshaw, H. B. (2010) N-Arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci. 11, 44
136. Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., and Compton, D. R. (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50, 83-90
137. Okuno, T., and Yokomizo, T. (2011) What is the natural ligand of GPR55? J. Biochem. 149, 495-497
138. Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N. O., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., and Greasley, P. J. (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol. 152, 1092-1101
139. Sugiura, T., Kodaka, T., Nakane, S., Miyashita, T., Kondo, S., Suhara, Y., Takayama, H., Waku, K., Seki, C., Baba, N., and Ishima, Y. (1999) Evidence that the cannabinoid CB1 receptor is a 2-Arachidonoylglycerol receptor. Structure-Activity relationship of 2-Arachidonoylglycerol, ether-linked analogues, and related compounds. J. Biol. Chem. 274, 2794-2801
140. Sugiura, T., Kondo, S., Kishimoto, S., Miyashita, T., Nakane, S., Kodaka, T., Suhara, Y., Takayama, H., and Waku, K. (2000) Evidence that 2-Arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J. Biol. Chem. 275, 605-612
141. Járai, Z., Wagner, J. A., Varga, K., Lake, K. D., Compton, D. R., Martin, B. R., Zimmer, A. M., Bonner, T. I., Buckley, N. E., Mezey, E., Razdan, R. K., Zimmer, A., and Kunos, G. (1999) Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. U. S. A. 96, 14136-14141
142. Johns, D. G., Behm, D. J., Walker, D. J., Ao, Z., Shapland, E. M., Daniels, D. A., Riddick, M., Dowell, S., Staton, P. C., Green, P., Shabon, U., Bao, W., Aiyar, N., Yue, T. L., Brown, A. J., Morrison, A. D., and Douglas, S. A. (2007) The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br. J. Pharmacol. 152, 825-831
143. Hillard, C. J., Manna, S., Greenberg, M. J., Di Camelli, R., Ross, R. A., Stevenson, L. A., Murphy, V., Pertwee, R. G., and Campbell, W. B. (1999) Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J. Pharmacol. Exp. Ther. 289, 1427-1433
144. Pertwee, R. G. (1999) Pharmacology of cannabinoid receptor ligands. Curr. Med. Chem. 6, 635-664
145. Hillard, C. J. (2000) Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-Arachidonylglycerol. Prostaglandins Other Lipid Mediat. 61, 3-18
146. Costa, B., Giagnoni, G., Franke, C., Trovato, A. E., and Colleoni, M. (2004) Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Br. J. Pharmacol. 143, 247-250
147. 9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci. 63, PL1-6
148. Thomas, A., Baillie, G. L., Phillips, A. M., Razdan, R. K., Ross, R. A., and Pertwee, R. G. (2007) Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br. J. Pharmacol. 150, 613-623
149. Caterina, M. J., Schumacher, M. A., Tominaga, M., Rosen, T. A., Levine, J. D., and Julius, D. (1997) The capsaicin receptor: a heat-Activated ion channel in the pain pathway. Nature 389, 816-824
150. Hanus, L., Breuer, A., Tchilibon, S., Shiloah, S., Goldenberg, D., Horowitz, M., Pertwee, R. G., Ross, R. A., Mechoulam, R., and Fride, E. (1999) HU-308: a specific agonist for CB (2), a peripheral cannabinoid receptor. Proc. Natl. Acad. Sci. U. S. A. 96, 14228-14233
151. Caldwell, M. D., Hu, S. S., Viswanathan, S., Bradshaw, H., Kelly, M. E., and Straiker, A. (2013) A GPR18-based signalling system regulates IOP in murine eye. Br. J. Pharmacol. 169, 834-843
152. Kohno, M., Hasegawa, H., Inoue, A., Muraoka, M., Miyazaki, T., Oka, K., and Yasukawa, M. (2006) Identification of N-Arachidonylglycine as the endogenous ligand for orphan G-protein-coupled receptor GPR18. Biochem. Biophys. Res. Commun. 347, 827-832
153. Lu, V. B., Puhl, H. L., 3rd, and Ikeda, S. R. (2013) N-Arachidonyl glycine does not activate G protein-coupled receptor 18 signaling via canonical pathways. Mol. Pharmacol. 83, 267-282
154. McHugh, D., Page, J., Dunn, E., and Bradshaw, H. B. (2012) Δ (9) - Tetrahydrocannabinol and N-Arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells. Br. J. Pharmacol. 165, 2414-2424
155. Sheskin, T., Hanus, L., Slager, J., Vogel, Z., and Mechoulam, R. (1997) Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J. Med. Chem. 40, 659-667
156. D'Ambra, T. E., Estep, K. G., Bell, M. R., Eissenstat, M. A., Josef, K. A., Ward, S. J., Haycock, D. A., Baizman, E. R., Casiano, F. M., and Beglin, N. C. (1992) Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl) indole agonists of the cannabinoid receptor. J. Med. Chem. 35, 124-135
157. Russo, E. B., Burnett, A., Hall, B., and Parker, K. K. (2005) Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem. Res. 30, 1037-1043